These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 16262110)

  • 1. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction.
    Margolese HC; Chouinard G; Kolivakis TT; Beauclair L; Miller R
    Can J Psychiatry; 2005 Aug; 50(9):541-7. PubMed ID: 16262110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.
    Margolese HC; Chouinard G; Kolivakis TT; Beauclair L; Miller R; Annable L
    Can J Psychiatry; 2005 Oct; 50(11):703-14. PubMed ID: 16363464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The current status of tardive dyskinesia.
    Sachdev PS
    Aust N Z J Psychiatry; 2000 Jun; 34(3):355-69. PubMed ID: 10881961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
    Seigneurie AS; Sauvanaud F; Limosin F
    Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia.
    Miller R; Chouinard G
    Biol Psychiatry; 1993 Nov; 34(10):713-38. PubMed ID: 7904833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiology of antipsychotic drug-induced movement disorders.
    Casey DE
    J Clin Psychiatry; 2004; 65 Suppl 9():25-8. PubMed ID: 15189109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tardive dyskinesia: pathophysiology and animal models.
    Casey DE
    J Clin Psychiatry; 2000; 61 Suppl 4():5-9. PubMed ID: 10739324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can atypical antipsychotics improve tardive dyskinesia associated with other atypical antipsychotics? Case report and brief review of the literature.
    Peritogiannis V; Tsouli S
    J Psychopharmacol; 2010 Jul; 24(7):1121-5. PubMed ID: 19395427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence.
    Kane JM
    J Clin Psychiatry; 2004; 65 Suppl 9():16-20. PubMed ID: 15189107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity.
    Bressan RA; Jones HM; Pilowsky LS
    J Psychopharmacol; 2004 Mar; 18(1):124-7. PubMed ID: 15107196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms.
    Lewis R
    Can J Psychiatry; 1998 Aug; 43(6):596-604. PubMed ID: 9729687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials.
    Lockwood JT; Remington G
    Expert Opin Emerg Drugs; 2015 Sep; 20(3):407-21. PubMed ID: 26166007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New and emerging treatments for symptomatic tardive dyskinesia.
    Rana AQ; Chaudry ZM; Blanchet PJ
    Drug Des Devel Ther; 2013; 7():1329-40. PubMed ID: 24235816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.
    Andrew HG
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
    Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia.
    Tsai G; Goff DC; Chang RW; Flood J; Baer L; Coyle JT
    Am J Psychiatry; 1998 Sep; 155(9):1207-13. PubMed ID: 9734544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia.
    Chakos MH; Alvir JM; Woerner MG; Koreen A; Geisler S; Mayerhoff D; Sobel S; Kane JM; Borenstein M; Lieberman JA
    Arch Gen Psychiatry; 1996 Apr; 53(4):313-9. PubMed ID: 8634009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The emerging role of atypical antipsychotics in the treatment of tardive dyskinesia induced by other atypical antipsychotics.
    Peritogiannis V; Tsouli S
    J Clin Psychiatry; 2011 Jul; 72(7):1016; author reply 1016-7. PubMed ID: 21824463
    [No Abstract]   [Full Text] [Related]  

  • 19. Pathophysiological mechanisms underlying tardive dyskinesia.
    Gerlach J
    Psychopharmacology Suppl; 1985; 2():98-103. PubMed ID: 2860666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Putative role of pharmacogenetics to elucidate the mechanism of tardive dyskinesia in schizophrenia.
    Loonen AJ; Wilffert B; Ivanova SA
    Pharmacogenomics; 2019 Nov; 20(17):1199-1223. PubMed ID: 31686592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.